Claturafenib - Pfizer
Alternative Names: ARRY-440; PF-07799933Latest Information Update: 21 Jul 2026
At a glance
- Originator Array BioPharma
- Developer Pfizer
- Class Amines; Antineoplastics; Azetidines; Chlorine compounds; Fluorine compounds; Ketones; Quinazolines; Small molecules; Sulfonamides
- Mechanism of Action
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 21 Jul 2026 Pfizer completes a phase I trial (In volunteers) in the US (PO, Tablet) (NCT07563894)
- 02 Jun 2026 Efficacy and adverse events data from phase I clinical trials in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 12 May 2026 Pfizer initiates enrolment in a phase I trial in (In volunteers) in the US (PO, Tablet) (NCT07563894)